alexa Relevance Of Non-clinical Data For Cell Therapy Development
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Conference on Translational & Personalized Medicine
August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Uri Herzberg
ScientificTracks Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.008
Abstract
Cell therapy is arguably the most complex drug development endeavor. A living organism is introduced into a patient, and a dynamic interaction between the patient?s biology and the therapeutic product is initiated. It is hoped that the end result of this interaction will be a positive therapeutic effect and possibly disease modification. As with most other therapeutic interventions, prior to human trials non-clinical testing is conducted. Assessment of human cells in a non-human setting is typically more complex than the testing of small molecules, peptides or biologics. While the xenogeneic challenge of assessing product safety can be addressed using specific mouse and rat strains, models of efficacy to demonstrate proof of concept, define dosing regimens and optimal route of administration in immune compromised animals are scarce. Celgene Cellular Therapeutics is developing placental derived adherent cells (PDAC) for the treatment of inflammatory, vascular, neurological, and autoimmune diseases. Using examples from the PDAC program and other cell based products, we will discuss the utility of non-clinical and translational studies in the development of cell based therapeutics. The development of appropriate models to address both safety and efficacy questions will be described. We will provide examples of how information from safety and biodistribution studies should be used along with data from various disease models to evaluate safety, efficacy, and mechanisms of action. Integrating these activities with translational studies to design a program that supports clinical development in the most efficient manner will also be discussed.
Biography
Uri Herzberg is the Senior Director of Preclinical and Translational Development at Celgene Cellular Therapeutics, a Division of Celgene Corporation. He obtained his veterinary training at Washington State University. He left veterinary practice and completed a Ph.D. in Neuroimmunology at the University of Minnesota, which was followed by post doctoral training at the NIH. He held positions of increased responsibilities at Cytotherapeutics, Acorda Therapeutics, Neurogen, and Johnson and Johnson where he was awarded the distinction of Excellence in Science. He is experienced with the discovery and early development of medical devices, small molecules, biologics, and cell-based therapeutics.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version